Immorta Bio, Inc.
About Immorta Bio, Inc.
Immorta Bio, Inc. is a regenerative medicine company dedicated to providing patient-specific therapeutic solutions for treating diseases of aging and treating aging as a disease. The company develops personalized stem cell technologies, including SenoVax™ senolytic immunotherapy and StemCellRevivify™ for cellular rejuvenation and exosomes, aimed at rejuvenating damaged organs. It focuses on restoring youthful biology through patient-derived rejuvenated stem cells and enhanced immune cells. Founded in 2023 and based in Miami Beach, Florida, the company has fewer than 10 employees.
- 🔗 Immorta Bio raises $450,000 Venture Series Unknown round (January 2026)
- 🔗 Immorta Bio - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Immorta Bio Inc, a Longevity Company, Announces a Significant Breakthrough in Treatment of Liver Failure
- 🔗 Immorta Bio Reports Preclinical Activity of Senolytic Immunotherapy SenoVax™ in a Chronic Traumatic Encephalopathy (CTE) Model
- 🔗 Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Strategic Advisory Board
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $450K in total funding across one reported round.
- Announced preclinical activity of SenoVax™ in a chronic traumatic encephalopathy model.
- Reported a breakthrough in treatment of liver failure using its stem cell platform.
- Appointed former Ernst & Young Health Sciences Partner Howard Brooks to its strategic advisory board.
- Advancing programs toward clinical development with a growing IP portfolio.
Ask StreetZero about Immorta Bio, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account